RECRUITINGPhase 2INTERVENTIONAL

Evaluating the Safety and Efficacy of Carbocisteine in the Treatment of Nonalcoholic Fatty Liver Disease Patients

About This Trial

Nonalcoholic fatty liver disease (NAFLD) is a global public health concern, and the leading cause of chronic liver disease, especially in developed countries. NAFLD is characterized by lipid accumulation in the liver not attributed to other causes. Lifestyle interventions, including dietary modification and exercise, remain the cornerstone of NAFLD treatment. Pharmacological treatments aimed primarily at improving liver disease should generally be limited to those with biopsy-proven NASH and fibrosis.

Who May Be Eligible (Plain English)

Who May Qualify: - Either male or female adult patients (\>18 years) with fatty liver diagnosis by using upper abdominal ultrasound echography Who Should NOT Join This Trial: - Pregnant and/or lactating women - Excessive alcohol use (defined as an average alcohol intake \> 30 g per day in men and \> 20 g per day in women) - Other etiology of chronic liver diseases such as viral hepatitis, drug-induced hepatitis, autoimmune hepatitis. - patients suffering from chronic kidney disease, and hyper/hypoparathyroidism - Hypersensitivity to carbocistiene. Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language

Inclusion Criteria: * Either male or female adult patients (\>18 years) with fatty liver diagnosis by using upper abdominal ultrasound echography Exclusion Criteria: * Pregnant and/or lactating women * Excessive alcohol use (defined as an average alcohol intake \> 30 g per day in men and \> 20 g per day in women) * Other etiology of chronic liver diseases such as viral hepatitis, drug-induced hepatitis, autoimmune hepatitis. * patients suffering from chronic kidney disease, and hyper/hypoparathyroidism * Hypersensitivity to carbocistiene.

Treatments Being Tested

DRUG

Carbocysteine 375 MG

Carbocysteine is a muco-active drug with free radical scavenging and anti-inflammatory properties. It is actually approved for clinical use as adjunctive therapy of respiratory tract disorders

OTHER

Physical activity, walking, and calorie restriction

• The standard conventional therapy in both groups included regular exercise in the form of any physical activity as walking, cycling, etc. for 30-45 minutes minimum 5 days per week in addition to calorie restriction in overweight and obese patients

Locations (1)

Tanta Unuversity

Tanta, Egypt